Eli Lilly: Worries Ahead In Patent Fight
May 17, 2017 at 12:39 PM EDT
Do investors under appreciate the downside risk the drug maker could face if it loses the next leg of the patent challenge on the cancer drug Alimta?
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|